Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TKT | P29401 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10954513 | 0.98 | LMNA (0.42) | LMNATSHRCYP1A2BLMNFKB1 | |
| SCHEMBL29953076 | 0.80 | MEN1 (0.36) | LMNATSHRCYP1A2BLMKDM4E | |
| SCHEMBL17677224 | 0.79 | LMNA (0.43) | LMNATSHRCYP1A2BLMNFKB1 | |
| SCHEMBL4832458 | 0.79 | LMNA (0.43) | LMNATSHRCYP1A2BLMNFKB1 | |
| SCHEMBL4716502 | 0.78 | — | — | |
| SCHEMBL13348654 | 0.77 | MEN1 (0.33) | LMNATSHRCYP1A2BLMKDM4E | |
| SCHEMBL7274718 | 0.76 | LMNA (0.41) | LMNATSHRCYP1A2BLMNFKB1 | |
| SCHEMBL29954024 | 0.75 | CYP1A2 (0.46) | LMNATSHRCYP1A2BLMKDM4E | |
| SCHEMBL4072762 | 0.75 | — | — | |
| SCHEMBL5674156 | 0.75 | CYP1A2 (0.46) | LMNATSHRCYP1A2BLMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4587014-A2 | C5AR1 ANTAGONISTS AND USES THEREOF | Vanqua Bio, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| WO-2024059096-A2 | C5AR1 ANTAGONISTS AND USES THEREOF | VANQUA BIO, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11365196-B2 | FGFR inhibitor and application thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-06-21 | — | — | US | disclosed |
| CN-109503496-B | Pyruvic acid dehydrogenase inhibitor compound and preparation method and application thereof | 华中师范大学 | 2021-12-21 | — | — | CN | disclosed |
| US-20210130353-A1 | FGFR INHIBITOR AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2021-05-06 | — | — | US | disclosed |
| US-10947206-B2 | cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| CN-107382877-A | A kind of synthetic method of 4 amino 2 methyl 5 (bromomethyl) pyrimidine hydrobromate | 成都百事兴科技实业有限公司 | 2017-11-24 | — | — | CN | disclosed |
| CN-105254574-B | A kind of simple and convenient process for preparing of the cyanopyrimidine of 2 methyl of vitamin B1 key intermediate, 4 amino 5 | 新发药业有限公司 | 2017-11-14 | — | — | CN | disclosed |
| US-9732065-B2 | Cyclic aminomethyl pyrimidine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| EP-0124780-B1 | PROCESS FOR PREPARING 2-ALKYL-4-AMINO-5-AMINOMETHYLPYRIMIDINE | UBE INDUSTRIES, LTD. (JP) | 1988-03-02 | — | — | EP | disclosed |
| EP-0103126-B1 | PROCESS FOR PREPARING 4-AMINO-5-DIALKOXYMETHYLPYRIMIDINE DERIVATIVES | UBE INDUSTRIES, LTD. (JP) | 1987-03-04 | — | — | EP | disclosed |
| US-4539403-A | Process for the preparation of a 2-alkyl-4-amino-5-aminomethylpyrimidine | UBE INDUSTRIES, LTD. (JP) | 1985-09-03 | — | — | US | disclosed |
| US-4536577-A | Process for preparing 2-alkyl-4-amino-5-aminomethylpyrimidine | UBE INDUSTRIES, LTD. (JP) | 1985-08-20 | — | — | US | disclosed |
| US-4492792-A | Process for preparing 4-amino-5-dialkoxy-methylpyrimidine derivatives | UBE INDUSTRIES, LTD. (JP) | 1985-01-08 | — | — | US | disclosed |
| EP-0124780-A1 | Process for preparing 2-alkyl-4-amino-5-aminomethylpyrimidine | UBE INDUSTRIES, LTD. (JP) | 1984-11-14 | — | — | EP | disclosed |
| EP-0103126-A1 | Process for preparing 4-amino-5-dialkoxymethylpyrimidine derivatives | UBE INDUSTRIES, LTD. (JP) | 1984-03-21 | — | — | EP | disclosed |
| EP-0018151-B1 | 6-SUBSTITUTED-ARYLPYRIDO(2,3-D)PYRIMIDIN-7-AMINES, DERIVATIVES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING ANY OF THE FOREGOING, AND PROCESSES FOR PRODUCING ANY OF THE FOREGOING | WARNER-LAMBERT COMPANY (US) | 1984-01-25 | — | — | EP | disclosed |
| US-4271164-A | HYPOTENSIVE AGENTS | WARNER-LAMBERT COMPANY (US) | 1981-06-02 | — | — | US | disclosed |
| EP-0018151-A1 | 6-Substituted-arylpyrido(2,3-d)pyrimidin-7-amines, derivatives and salts thereof, pharmaceutical compositions containing any of the foregoing, and processes for producing any of the foregoing | WARNER-LAMBERT COMPANY (US) | 1980-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947206-B2 | cGAS antagonist compounds | CGAS, STING1, GLS2 | LMNA 1551/4885TSHR 2334/4885CYP1A2 2067/4885 |
| US-11365196-B2 | FGFR inhibitor and application thereof | FGFR1, FGFR4, FGFR2 | LMNA 4231/4885TSHR 3174/4885CYP1A2 2637/4885 |
| US-20210130353-A1 | FGFR INHIBITOR AND APPLICATION THEREOF | FGFR1, FGFR4, FGFR2 | LMNA 4168/4885TSHR 3434/4885CYP1A2 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.